Actively Recruiting
Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Gastroesophageal Cancers
Led by Blokhin's Russian Cancer Research Center · Updated on 2026-03-12
30
Participants Needed
1
Research Sites
130 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
GENCONCOR-2 is a translational research aimed to compare the molecular profile of primary tumors and their matched brain metastases in gastroesophageal cancers, including cancer of the esophagus, gastroesophageal junction, and stomach. The study is based on the previously established international GASTROBRAIN cohort (ClinicalTrials.gov ID: NCT07448493), which provides comprehensive clinicopathological and treatment data for over 230 patients. It will be conducted by retrospective analysis of paired samples of histological material (primary tumor and corresponding brain metastasis) with determination of HER2 expression status (IHC ± FISH), MSI status (IHC ± PCR), PD-L1 combined positive score (CPS), and CLDN18.2 expression status (IHC)
CONDITIONS
Official Title
Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Gastroesophageal Cancers
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18 years or older included in the GASTROBRAIN study with clinicopathological and treatment data available
- Histologically confirmed gastric adenocarcinoma, esophageal carcinoma (adenocarcinoma or squamous cell carcinoma), or gastroesophageal junction adenocarcinoma
- History of neurosurgical removal of brain metastases with available archived tissue
- Availability of paired formalin-fixed paraffin-embedded tissue samples from primary tumor and matched brain metastasis
You will not qualify if you...
- Presence of multiple primary cancers involving other sites besides the stomach, esophagus, or gastroesophageal junction
- Primary tumor located outside the gastrointestinal tract
- Histologically confirmed non-epithelial gastrointestinal cancers such as neuroendocrine tumors, sarcoma, gastrointestinal stromal tumor, or lymphoma
- Brain metastases limited to skull bones or soft tissues without brain parenchymal involvement
- Tumor cell content less than 70% in microdissected area or poor sample quality affecting molecular testing
- Missing either the primary tumor or brain metastasis tissue sample from the paired set
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Blokhin's Russian Cancer Research Center
Moscow, Russia, 115478
Actively Recruiting
Research Team
D
David Khalafyan, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here